SCHEMBL4774743

SCHEMBL4774743

COC(=O)c1ccc(N(Cc2ccccc2Cl)S(C)(=O)=O)cc1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.60
GAA P10253 2/20 0.59
MAPT P10636 2/20 0.57
POLB P06746 3/20 0.49
RAB9A P51151 2/20 0.49
NPC1 O15118 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.48
MEN1 O00255 2/20 0.47
LMNA P02545 2/20 0.47
KMT2A Q03164 2/20 0.47
RECQL P46063 1/20 0.44
HPGD P15428 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
KDM4E B2RXH2 1/20 0.43
TSHR P16473 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4777409 0.90 ALDH1A1 (0.51) ALDH1A1GAAMAPTPOLBRAB9A
SCHEMBL14497659 0.86 GAA (0.59) ALDH1A1GAAMAPTPOLBSMN1; SMN2
SCHEMBL4768069 0.85 GAA (0.64) ALDH1A1GAAMAPTPOLBSMN1; SMN2
SCHEMBL4777536 0.85 GAA (0.58) ALDH1A1GAAMAPTPOLBMEN1
SCHEMBL4777288 0.84 GAA (0.61) ALDH1A1GAAMAPTPOLBMEN1
SCHEMBL4776615 0.83 GAA (0.68) ALDH1A1GAAMAPTPOLBSMN1; SMN2
SCHEMBL4771155 0.82 MAPT (0.56) ALDH1A1GAAMAPTPOLBMEN1
SCHEMBL4777650 0.81 GAA (0.60) ALDH1A1GAAMAPTPOLBSMN1; SMN2
SCHEMBL4777696 0.81 GAA (0.66) ALDH1A1GAAMAPTPOLBSMN1; SMN2
SCHEMBL4772417 0.81 GAA (0.66) ALDH1A1GAAMAPTPOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 ALDH1A1 2159/4885GAA 466/4885MAPT 294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.